The second largest group of mutations in Ph-like ALL comprises ABL-class fusions (ABL1, ABL2, CSF1R, PDGFRB), that are predicted to respond to ABL1 inhibitors. Here, ABL1 is linked to acute lymphoblastic leukemia.